Takeda Receives US FDA Approval for Nelkarmi (neladalkib) in ALK-Positive NSCLC
The US Food and Drug Administration has approved Takeda's Nelkarmi (neladalkib) for the treatment of patients with previously-treated advanced ALK-positive non-small cell lung cancer.